Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

  title={Randomized trial of oral teriflunomide for relapsing multiple sclerosis.},
  author={P. W. O'Connor and Jerry S. Wolinsky and Christian Confavreux and Giancarlo Comi and Ludwig Kappos and Tomas P. Olsson and Hadj Benzerdjeb and Philippe Truffinet and Lin Wang and Aaron E Miller and Mark Steven Freedman},
  journal={The New England journal of medicine},
  volume={365 14},
BACKGROUND Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS We concluded a randomized trial involving 1088 patients with multiple sclerosis, 18 to 55 years of age, with a score of 0 to 5.5 on the Expanded Disability Status Scale and at least one relapse in the previous year or at least two relapses in the previous 2 years. Patients were randomly assigned (in a 1:1:1 ratio) to placebo, 7 mg of teriflunomide, or 14 mg of teriflunomide once… 

Figures and Tables from this paper

Multiple sclerosis: Teriflunomide shows promise for MS treatment in phase III trial

  • H. Wood
  • Medicine, Psychology
    Nature Reviews Neurology
  • 2011
The oral drug teriflunomide reduces relapse rates, disability progression and MRI disease activity in patients with relapsing multiple sclerosis (MS), according to the results of a randomized,

A randomized trial of teriflunomide added to glatiramer acetate in relapsing multiple sclerosis

Teriflunomide added to stable-dose GA had acceptable safety and tolerability, and reduced some MRI markers of disease activity compared with GA alone.

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial

Once-daily treatment with ponesimod 10, 20 or 40 mg significantly reduced the number of new T1 Gd+ lesions and showed a beneficial effect on clinical endpoints.

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis

Data from the clinical development program support the use of teriflunomide in a broad spectrum of patients with RRMS, with reference to key clinical and safety outcomes and practical considerations for prescribing physicians.

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.

Ponesimod was superior to teriflunomide on relapse rate reduction, fatigue, brain volume loss, and no evidence of disease activity on magnetic resonance imaging activity, and time to 12-week and 24-week confirmed disability accumulation.

Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study

The results support efficacy and tolerability of teriflunomide for treatment-naïve RRMS patients in real-world practice and suggest female patients, patients with less relapses and less disability before treatment are most likely to benefit from terifnomide treatment.



A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Both doses of oral fingolimod improved the relapse rate, the risk of disability progression, and end points on MRI and were superior to placebo with regard to MRI-related measures.

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

Oral teriflunomide was effective in reducing MRI lesions and was well tolerated in patients with relapsing multiple sclerosis and resulted in trends toward a lower annualized relapse rate and fewer relapsesing patients vs placebo.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.

Management of Relapsing-Remitting Multiple Sclerosis

SummarySubcutaneous (SC) interferon-β-1a (Rebif®1) is a disease-modifying therapy that demonstrates significant benefits on all outcome measures of clinical trials [relapse rate, relapse severity,

Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.

Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis

The MRI results demonstrate that IFNB has made a significant impact on the natural history of MS in these patients and support the clinical results in showing a significant reduction in disease activity as measured by numbers of active scans and appearance of new lesions.

Assessing changes in relapse rates in multiple sclerosis

ARRs have fallen with relapse definition, entrance criteria remain important, but time exceeds all these variables and reflects two likely sources, selection of patients for trials by clinicians and rescue of patients truncating the number of multiple relapses.

Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis

Leflunomide remains one of the most useful of the nonbiologic DMARDs and practical advice informed by evidence is given regarding dosing regimens, safety monitoring, and managing side effects.

Review of teriflunomide and its potential in the treatment of multiple sclerosis

With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.